Case Study on Formulating a Multidose Lyophilized Measles-Rubella (MR) Vaccine Candidate for Local Manufacturing in Africa: Lab-Scale Results and Lessons Learned for Future Technology Transfer.
- 1Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, The University of Kansas, Lawrence, KS 66047, USA.
- 2Vaccine Research Center (VRC), Institut Pasteur de Dakar (IPD), Dakar B.P. 220, Senegal.
Abstract
Background/Objectives: Local manufacturing of Measles-Rubella (MR) vaccines is part of a multifaceted approach to improve vaccine accessibility in Africa, yet process development and technology transfer challenges remain for large-scale production of viral bulks and lyophilized drug product. This case study describes lab-scale formulation development of a multidose, lyophilized MR vaccine candidate, leveraging the availability of concentrated bulks of Measles (MeV) and Rubella (RuV) produced in MRC-5 cells by a new bulk manufacturing process. Methods: Formulation studies utilized both high-throughput RT-qPCR viral infectivity assays and standard lyophilization measurements. The off-patent, publicly available formulation composition of a single-dose, lyophilized trivalent MMR vaccine was evaluated as a starting point to develop a multidose, bivalent lyophilized MR vaccine candidate. To identify optimized conditions, various formulation (e.g., human serum albumin, viral bulk volume), drug product (e.g., vial size, fill volume), and lyophilization (e.g., freezing rate, primary/secondary drying cycle) parameters were evaluated to lower costs and assess MR stability during lyophilization, storage, and reconstitution. Results: Real-time and accelerated stability studies were conducted with four variations of the top candidate MR formulation, filled into primary packaging selected for technology transfer and lyophilized in both lab- and pilot- scale freeze-dryers. An optimized five-dose MR vaccine formulation with 5% (v/v) bulk and 95% (v/v) stabilizer solution, filled at 2X and reconstituted to 1X concentrations, demonstrated promising stability profiles and cost reduction potential. Stability profiles at 2-8 °C were used to estimate the MR release doses needed to ensure the required expiry doses at end of shelf-life. Conclusions: Results are discussed, along with recommendations for future work, in the context of the analytical, formulation, and lyophilization challenges encountered during lab-scale development of a candidate multidose, lyophilized MR vaccine dosage form targeted for technology transfer and large-scale local production in Africa.
Related
- An Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder.
- Development and quality evaluation of lyophilized plasma external quality assessment samples for coagulation testing in resource-limited settings
- Vision-Related Quality of Life and Dry Eye Symptoms After Treatment with Lyophilized Amniotic Membrane Eye Drops: A Secondary Analysis of a Prospective Cohort Study
- Identifying and formulating appropriate clinical problems for clinical prediction models and AI decision support: the RIVU-AI framework.
- Pharmacokinetic/pharmacodynamic evaluation of multidose oritavancin for prolonged durations of therapy
BibTeX
@article{secrist2026case,
title = {{Case Study on Formulating a Multidose Lyophilized Measles-Rubella (MR) Vaccine Candidate for Local Manufacturing in Africa: Lab-Scale Results and Lessons Learned for Future Technology Transfer.}},
author = {Kathryn Secrist and Prashant Kumar and Michael Z Wang and Soraia Saleh-Birdjandi and Sagar Salave and Ozan S Kumru and Ngana Salem Mberkadji and Fama Sakho and Sangeeta B Joshi and David B Volkin},
journal = {Vaccines},
year = {2026},
month = oct,
doi = {10.3390/vaccines14100900},
url = {https://europepmc.org/article/MED/42931429},
note = {CC BY},
}
RIS
TY - JOUR
TI - Case Study on Formulating a Multidose Lyophilized Measles-Rubella (MR) Vaccine Candidate for Local Manufacturing in Africa: Lab-Scale Results and Lessons Learned for Future Technology Transfer.
AU - Kathryn Secrist
AU - Prashant Kumar
AU - Michael Z Wang
AU - Soraia Saleh-Birdjandi
AU - Sagar Salave
AU - Ozan S Kumru
AU - Ngana Salem Mberkadji
AU - Fama Sakho
AU - Sangeeta B Joshi
AU - David B Volkin
PY - 2026
DA - 2026/10/14
JO - Vaccines
DO - 10.3390/vaccines14100900
UR - https://europepmc.org/article/MED/42931429
AB - Background/Objectives: Local manufacturing of Measles-Rubella (MR) vaccines is part of a multifaceted approach to improve vaccine accessibility in Africa, yet process development and technology transfer challenges remain for large-scale production of viral bulks and lyophilized drug product. This case study describes lab-scale formulation development of a multidose, lyophilized MR vaccine candidate, leveraging the availability of concentrated bulks of Measles (MeV) and Rubella (RuV) produced in MRC-5 cells by a new bulk manufacturing process. Methods: Formulation studies utilized both high-throughput RT-qPCR viral infectivity assays and standard lyophilization measurements. The off-patent, publicly available formulation composition of a single-dose, lyophilized trivalent MMR vaccine was evaluated as a starting point to develop a multidose, bivalent lyophilized MR vaccine candidate. To identify optimized conditions, various formulation (e.g., human serum albumin, viral bulk volume), drug product (e.g., vial size, fill volume), and lyophilization (e.g., freezing rate, primary/secondary drying cycle) parameters were evaluated to lower costs and assess MR stability during lyophilization, storage, and reconstitution. Results: Real-time and accelerated stability studies were conducted with four variations of the top candidate MR formulation, filled into primary packaging selected for technology transfer and lyophilized in both lab- and pilot- scale freeze-dryers. An optimized five-dose MR vaccine formulation with 5% (v/v) bulk and 95% (v/v) stabilizer solution, filled at 2X and reconstituted to 1X concentrations, demonstrated promising stability profiles and cost reduction potential. Stability profiles at 2-8 °C were used to estimate the MR release doses needed to ensure the required expiry doses at end of shelf-life. Conclusions: Results are discussed, along with recommendations for future work, in the context of the analytical, formulation, and lyophilization challenges encountered during lab-scale development of a candidate multidose, lyophilized MR vaccine dosage form targeted for technology transfer and large-scale local production in Africa.
SN - 2076-393X
ER -